Latest Intelligence on Pharmaceuticals and Healthcare in Canada

Published within

« | 1 | 2 | 3 | 4 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Xenova/QLT: tackling multidrug resistance

UK biotech Xenova and its North American ally QLT will trial tariquidar for multidrug resistance in non-small cell lung cancer. As long as the results are positive, tariquidar should have a bright future: multidrug resistance is an increasingly serious problem in cancer treatment, and the developers look set to provide strong marketing support.

Published By Datamonitor
11 Jul 2002
CommentWire
CommentWire

Women's health: tamoxifen may do more harm than good

While the drug is undeniably highly effective at treating breast cancer, some of the efforts to use it as a preventative medicine may be more questionable. For many women, the side effects could prove more dangerous than the risk of breast cancer. More studies need to be carried out to determine exactly which groups will benefit from the drug.

Published By Datamonitor
05 Nov 2001
Expert View
Expert View

US online pharmacies can attract consumers from cross-border discounters

The trade in discounted prescription drugs between Canada and the US has elicited considerable controversy on both sides of the border. Yet recent figures show that sales of drugs via Canadian pharmacies have not been as great as some had predicted. However, as Datamonitor's David Deon explains, pharmaceutical companies could go further by driving the expansion of online prescribing in the US...

Published By Datamonitor
28 Jul 2004
CommentWire
CommentWire

Transition Therapeutics: showing potential in hepatitis

Toronto-based Transition Therapeutics has posted positive 12-week data from a phase I/II trial investigating the safety and efficacy of HCV-IET in hepatitis C non-responders. However, although its results to date look promising, the drug candidate looks set to face stiff competition from other pipeline products, several of which appear to have a head-start.

Published By Datamonitor
08 Aug 2006
CommentWire
CommentWire

Solvay/Biovail: too little, too late for Teveten

Although Solvay/Biovail's Teveten (eprosartan) has demonstrated benefits in isolated systolic hypertension, Solvay has been reluctant to file for this indication. The results of the most recent trial may well be too little too late now that Teveten's major competitors, such as Diovan (valsartan), are also targeting this indication.

Published By Datamonitor
21 May 2003
CommentWire
CommentWire

Shire: comeback conundrums

Canadian regulators have agreed to allow Shire's ADHD drug Adderall XR to return to the market following its temporary withdrawal earlier this year. This is good news for Shire as reinstatement of Adderall XR in Canada will help to re-establish both the drug's reputation and its share of the Canadian ADHD market. However, looking at the outlook for the drug in a wider context, it is no panacea.

Published By Datamonitor
26 Aug 2005
CommentWire
CommentWire

Shire Pharmaceuticals: transatlantic growth spurt

Published By Datamonitor
11 Dec 2000
CommentWire
CommentWire

Schering-Plough: Caelyx approved in Canada

Published By Datamonitor
06 Feb 2001
CommentWire
CommentWire

Sanofi-Aventis/BMS: patent victory pending?

Apotex and Dr Reddy's have been challenging Sanofi [SNY] and Bristol-Myers Squibb (BMS) [BMY] over a Plavix patent concerning a 'parent molecule', which expires in 2011. However, the fact that the challenge was rejected in Canada is a positive outcome for Sanofi and BMS and indicates that they could also win the case in the more important US market.

Published By Datamonitor
23 Mar 2005
CommentWire
CommentWire

Sanofi-Aventis/BMS: a Plavix plague on both their houses?

Canadian generics firm Apotex has received an approval from the FDA to launch a generic version of Sanofi-Aventis and Bristol-Myers Squibb's blockbuster heart drug Plavix. This is bad, although expected, news for the two pharma giants, which both need to stave off such generic threats. However, the companies are not going down without a fight, as Sanofi-Aventis' patent infringement filing shows.

Published By Datamonitor
27 Jan 2006

« | 1 | 2 | 3 | 4 | » »|

No help is available.